Kangstem Biotech Decides on 48 Billion KRW Rights Offering

Kangstem Biotech, a KOSDAQ-listed company, announced on the 10th that it has decided to raise approximately 48 billion KRW through a rights offering followed by a public offering of forfeited shares, in order to secure operating funds and for other purposes.